Literature DB >> 18806690

Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats.

Ann Massie1, Anneleen Schallier, Birgit Mertens, Katia Vermoesen, Shiro Bannai, Hideyo Sato, Ilse Smolders, Yvette Michotte.   

Abstract

Altered glutamate signaling is associated with Parkinson's disease. To study the involvement of the cystine/glutamate antiporter in the pathogenesis of Parkinson's disease, we developed new polyclonal antibodies recognizing xCT, the specific subunit of this antiporter. The striatal xCT protein expression level was investigated in a hemi-Parkinson rat model, using semiquantitative western blotting. We observed time-dependent changes after a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway with increased expression levels in the deafferented striatum after 3 weeks. Twelve weeks postlesion, expression levels returned to normal. These data suggest, for the first time, an involvement of the cystine/glutamate antiporter in determining the aberrant glutamate neurotransmission in the striatum of a parkinsonian brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806690     DOI: 10.1097/WNR.0b013e328312181c

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  18 in total

Review 1.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Authors:  Jan Lewerenz; Sandra J Hewett; Ying Huang; Maria Lambros; Peter W Gout; Peter W Kalivas; Ann Massie; Ilse Smolders; Axel Methner; Mathias Pergande; Sylvia B Smith; Vadivel Ganapathy; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2012-08-03       Impact factor: 8.401

2.  In silico characterization of residues essential for substrate binding of human cystine transporter, xCT.

Authors:  Monika Sharma; C R Anirudh
Journal:  J Mol Model       Date:  2019-11-09       Impact factor: 1.810

3.  Non-invasive Use of Positron Emission Tomography to Monitor Diethyl maleate and Radiation-Induced Changes in System xC- Activity in Breast Cancer.

Authors:  Milena Čolović; Hua Yang; Helen Merkens; Nadine Colpo; François Bénard; Paul Schaffer
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

4.  Transport of BMAA into Neurons and Astrocytes by System xc.

Authors:  Rebecca Albano; Doug Lobner
Journal:  Neurotox Res       Date:  2017-05-03       Impact factor: 3.911

5.  System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.

Authors:  Pinar Mesci; Sakina Zaïdi; Christian S Lobsiger; Stéphanie Millecamps; Carole Escartin; Danielle Seilhean; Hideyo Sato; Michel Mallat; Séverine Boillée
Journal:  Brain       Date:  2014-11-10       Impact factor: 13.501

Review 6.  Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling.

Authors:  Richard Bridges; Victoria Lutgen; Doug Lobner; David A Baker
Journal:  Pharmacol Rev       Date:  2012-07       Impact factor: 25.468

Review 7.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

Review 8.  Main path and byways: non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission.

Authors:  Ann Massie; Séverine Boillée; Sandra Hewett; Lori Knackstedt; Jan Lewerenz
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

9.  Increased expression of cystine/glutamate antiporter in multiple sclerosis.

Authors:  Olatz Pampliega; María Domercq; Federico N Soria; Pablo Villoslada; Alfredo Rodríguez-Antigüedad; Carlos Matute
Journal:  J Neuroinflammation       Date:  2011-06-03       Impact factor: 8.322

10.  Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Authors:  Jan Lewerenz; Paul Baxter; Rebecca Kassubek; Philipp Albrecht; Joeri Van Liefferinge; Mike-Andrew Westhoff; Marc-Eric Halatsch; Georg Karpel-Massler; Paul J Meakin; John D Hayes; Eleonora Aronica; Ilse Smolders; Albert C Ludolph; Axel Methner; Marcus Conrad; Ann Massie; Giles E Hardingham; Pamela Maher
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.